Treatment of Pneumocystis Pneumonia (PCP) in Immunocompromised Patients

Initial Management

The American College of Physicians recommends beginning high-dose trimethoprim-sulfamethoxazole (TMP-SMX) immediately upon suspicion of PCP, even before bronchoscopy and bronchoalveolar lavage (BAL) if PCP is strongly suspected based on clinical presentation, elevated LDH, and radiographic findings 1
The British Thoracic Society suggests providing appropriate oxygen therapy with monitoring of oxygen saturations, aiming to maintain oxygen saturation >92% 2
The British Thoracic Society also recommends assessing for volume depletion and providing intravenous fluids as needed, and monitoring vital signs including temperature, respiratory rate, pulse, blood pressure, mental status, and oxygen saturation at least twice daily, or more frequently in severe cases 2

The American College of Physicians recommends alternative regimens for patients who cannot tolerate TMP-SMX due to adverse reactions, including clindamycin plus primaquine, pentamidine (intravenous), and atovaquone 1

The American College of Physicians suggests considering adjunctive glucocorticosteroids in patients with critical respiratory insufficiency due to PCP, although this is not generally recommended for non-HIV patients and should be evaluated on a case-by-case basis 1

The British Thoracic Society recommends measuring CRP levels to assess treatment response, and considering repeat chest radiography if the patient is not progressing satisfactorily 2
The American College of Physicians suggests monitoring for adverse effects of TMP-SMX, which commonly include dermatologic reactions (rash) and hematologic abnormalities (leukopenia, thrombocytopenia) 1

The American College of Physicians recommends pursuing diagnostic confirmation through induced sputum or bronchoalveolar lavage fluid examination using tinctorial staining or PCR, and triggering treatment if not already started for positive quantitative PCR (>1450 copies/ml) for P. jirovecii from BAL 1